Serina Therapeutics, Inc.
Business
Serina Therapeutics is a clinical-stage biotechnology company developing polymer-conjugated drug candidates using its proprietary POZ (poly(2-oxazoline)) platform technology for neurological diseases, particularly Parkinson's disease. The company's lead candidate, SER-252 (POZ-apomorphine), is in Phase 1b clinical trials for advanced Parkinson's disease, designed to deliver continuous dopaminergic stimulation via subcutaneous injection. Serina is also advancing POZ-lipid technology as a non-immunogenic alternative to PEG-lipids for lipid nanoparticle vaccines and has licensed POZ polymer technology to Pfizer for use in lipid nanoparticle drug delivery formulations.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 130,000 | 56,000 | 3 | 34,000 | 144,000 | |
| Research and development | 13 | 7 | 2 | 1 | 1 | |
| General and administrative | 11 | 10 | 4 | 6 | 7 | |
| Total operating expenses | 24 | 17 | 6 | 7 | 8 | |
| Loss from operations | −24 | −17 | −3 | −7 | −8 | |
| Interest expense | −213,000 | −526,000 | −558,000 | — | — | |
| Change in fair value of convertible promissory notes | 0 | −7 | 5 | — | — | |
| Change in fair value of warrants liabilities | 4 | 13 | 1 | −225,000 | — | |
| Gain on warrants expiration | 724,000 | 0 | — | — | — | |
| Other income, net | 51,000 | 228,000 | — | — | 448,000 | |
| Total other income, net | 5 | 6 | 8 | −4 | −649,000 | |
| Loss before income taxes | −19 | −11 | — | — | −9 | |
| Provision for income taxes | −18,000 | 0 | — | — | — | |
| Net loss | −19 | −11 | 5 | −11 | −9 | |
| Net loss attributable to noncontrolling interest | 33,000 | 66,000 | 0 | 60,000 | — | |
| NET LOSS ATTRIBUTABLE TO SERINA | −19 | −11 | 5 | −10 | −9 | |
| NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, BASIC | −19 | −11 | — | — | — | |
| NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, DILUTED | −19 | −11 | — | — | — | |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, BASIC (in usd per share) | −1.91 | −1.51 | 2.36 | −9.7 | −0.23 | |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, DILUTED (in usd per share) | −1.91 | −1.51 | 0.73 | −9.7 | — | |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, BASIC (in shares) | 10 | 7 | 2 | 1,079 | 38 | |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, DILUTED (in shares) | 10 | 7 | 7 | 1,079 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-09-30 | FY 2024 2024-06-30 | FY 2024 2024-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 4 | — | — | — | |
| Prepaid expenses and other current assets | 3 | 2 | — | — | — | |
| Total current assets | 6 | 6 | — | — | — | |
| Property and equipment, net | 465,000 | 501,000 | — | — | — | |
| Right of use assets - operating leases | 377,000 | 461,000 | — | — | — | |
| Right of use assets - finance leases | 0 | 86,000 | — | — | — | |
| Other long-term prepaid assets | 29,000 | 0 | — | — | — | |
| TOTAL ASSETS | 7 | 7 | — | — | — | |
| Accounts payable | 2 | 744,000 | — | — | — | |
| Accrued expenses | 1 | 1 | — | — | — | |
| Warrant liability | 88,000 | 0 | — | — | — | |
| Other current liabilities | 337,000 | 193,000 | — | — | — | |
| Total current liabilities | 4 | 2 | — | — | — | |
| Warrant liability, non-current | 283,000 | 4 | — | — | — | |
| Convertible Note, net | 3 | 0 | — | — | — | |
| Operating lease liabilities, net of current portion | 196,000 | 268,000 | — | — | — | |
| TOTAL LIABILITIES | 7 | 6 | — | — | — | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Series A convertible preferred stock, $0.0001 par value, 5,000 shares authorized; 965 and zero shares issued and outstanding at December 31, 2025 and 2024, respectively; liquidation preference of $5,000 and zero at December 31, 2025 and 2024, respectively; | 5 | 0 | — | — | — | |
| Common stock, $0.0001 par value, 40,000 shares authorized; and 10,767 and 9,422 shares issued and outstanding at December 31, 2025 and 2024, respectively; (including 57 shares declared as a stock dividend on April 1, 2025 and issued on March 31, 2026) | 1,000 | 1,000 | — | — | — | |
| Additional paid-in capital | 59 | 45 | 28 | 27 | 20 | |
| Accumulated other comprehensive loss | −14,000 | 0 | — | — | — | |
| Accumulated deficit | −64 | −44 | −42 | −43 | −48 | |
| Total Serina Therapeutics, Inc. stockholders (deficit) equity | −37,000 | 641,000 | — | — | — | |
| Noncontrolling deficit | 0 | −133,000 | — | — | — | |
| TOTAL STOCKHOLDERS' (DEFICIT) EQUITY | −37,000 | 508,000 | — | — | — | |
| TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY | 7 | 7 | — | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 73,000 | 194,000 | 90,000 | — | — | |
| Loss on disposal of property and equipment | 91,000 | 0 | — | — | — | |
| Non-cash lease expense | 203,000 | 227,000 | 174,000 | — | — | |
| Non-cash interest expense | 138,000 | 164,000 | 558,000 | — | — | |
| Amortization of debt issuance costs and debt discounts | 58,000 | 345,000 | 0 | 3 | 1 | |
| Stock-based compensation | 4 | 3 | — | — | — | |
| Common stock issued to consultant for services rendered | 226,000 | 0 | — | — | — | |
| Restricted stock units released to consultant for services rendered | 29,000 | 0 | — | — | — | |
| Change in fair value of convertible promissory notes | 0 | 7 | −5 | — | — | |
| Loss on sale of subsidiary | 166,000 | 0 | — | — | — | |
| Grant receivable | 0 | 65,000 | 0 | — | — | |
| Prepaid expenses and other assets | 673,000 | −2 | 16,000 | 896,000 | 760,000 | |
| Accounts payable | 1 | −2 | 393,000 | — | — | |
| Accrued expenses | −231,000 | 400,000 | −140,000 | — | — | |
| Other current liabilities | 18,000 | 0 | −4,000 | −4,000 | −79,000 | |
| Operating lease liabilities | −187,000 | −214,000 | −188,000 | — | — | |
| Net cash used in operating activities | −18 | −17 | −2 | −6 | −8 | |
| Purchase of equipment | −59,000 | −22,000 | — | — | — | |
| Net cash used in investing activities | −59,000 | −22,000 | −504,000 | — | 666,000 | |
| Proceeds from the issuance of common stock and warrants to Juvenescence | 0 | 5 | 0 | — | — | |
| Drawdown on loan facilities from Juvenescence | 0 | 3 | 0 | 6 | 7 | |
| Cash and restricted cash acquired in connection with the Merger | 0 | 337,000 | 0 | — | — | |
| Proceeds from the exercise of stock options | 15,000 | 12,000 | 15,000 | — | — | |
| Proceeds from the exercise of Post-Merger Warrants by Juvenescence | 0 | 5 | 0 | — | — | |
| Principal repayment on loan facilities to Juvenescence | 0 | −133,000 | 0 | — | — | |
| Principal repayments on finance lease liabilities | 0 | −35,000 | −48,000 | — | — | |
| Proceeds from issuance of Series A Convertible Preferred Stock, net | 5 | 0 | — | — | — | |
| Proceeds from 2025 Convertible Note, net | 5 | 0 | 10 | — | — | |
| Net cash provided by financing activities | 17 | 13 | 10 | 6 | 7 | |
| Effect of foreign currency on cash and cash equivalents | −14,000 | 0 | — | — | — | |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | −616,000 | −4 | 7 | 61,000 | 57,000 | |
| Cash paid during the year for interest | 17,000 | 0 | 27,000 | 14,000 | 13,000 | |
| Issuance of common stock upon conversion of redeemable convertible preferred stock | 0 | 36 | 0 | 8,000 | 16,000 | |
| Merger and issuance of common stock upon consummation of Merger on March 26, 2024 | 0 | 961,000 | 0 | — | — | |
| Deemed dividend from issuance of warrants | 0 | 19 | 0 | — | — | |
| Derecognition of Post Merger and Incentive Warrants liability upon exchange transaction | 0 | −2 | 0 | — | — | |
| Issuance of common stock warrants upon exchange transaction | 0 | 1 | 0 | — | — | |
| Issuance of common stock warrants upon exercise of Post-Merger warrants | 0 | 1 | — | — | — | |
| Extinguishment of debt upon sale of subsidiary | 0 | 11 | 0 | — | — | |
| Right of use asset acquired in exchange for operating lease liabilities | 115,000 | 0 | 755,000 | — | — | |
| Transfer of right-of-use assets to property and equipment upon title transfer | 75,000 | 0 | — | — | — | |
| Issuance of common stock warrants in connection with 2025 Convertible Note | 4 | 0 | — | — | — | |
| Recognition of debt discount on 2025 Convertible Note | 2 | 0 | — | — | — | |
| Reclassification of warrant liability to equity | 2 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Serina Therapeutics, Inc.'s CIK number?
Serina Therapeutics, Inc.'s SEC CIK number is 0001708599 (1708599). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Serina Therapeutics, Inc.'s SEC filings?
All of Serina Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Serina Therapeutics, Inc. last report earnings?
Serina Therapeutics, Inc. (SER) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001708599-26-000036). This is Serina Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Serina Therapeutics, Inc.'s most recent earnings 8-K?
Serina Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001708599-26-000036. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Serina Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →